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Edited by Laszlo NagyAbstract We focused on the functional involvement of trans-
forming growth factor-b-activated kinase 1 (TAK1) in transcrip-
tional regulation of interleukin-2 (IL-2) in T cells. Costimulation
of Jurkat cells with 12-O-tetradecanoylphorbol-13-acetate and
A23187 leads to a rapid phosphorylation of TAK1 and TAK1-
binding protein 1 (TAB1), critical for TAK1 activation. A spe-
ciﬁc inhibitor of TAK1 blocked production of IL-2. In addition,
overexpression of TAK1 and TAB1 induced secretion of IL-2.
CD28-responsive element/activator protein-1-binding site (RE/
AP) within the IL-2 promoter was a functional target for
TAK1. The RE/AP-driven transcription was regulated by
TAK1-mediated activation of the c-Jun NH2-terminal kinase,
p38 and IjB kinase. These results indicate that TAK1 plays a
critical role in T cell activation by controlling production of
IL-2.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transforming growth factor-b-activated kinase 1 (TAK1)
mitogen-activated protein kinase kinase kinase (MAP3K) has
been shown to play critical roles in signaling pathways stimu-
lated by pro-inﬂammatory cytokines such as tumor necrosis
factor-a (TNF-a) and interleukin-1 (IL-1) [1–3]. In addition,
lipopolysaccharide, a ligand for Toll-like receptor 4 (TLR4),
is known as a TAK1 activating agent in macrophages [4].
TAK1 has been shown to regulate c-Jun N-terminal kinase
(JNK)/p38 mitogen-activated protein kinase (MAPK) and
IjB kinase (IKK) signaling pathways, leading to the activation
of transcription factors activator protein-1 (AP-1) and nuclear
factor-jB (NF-jB) [5–8]. In addition, innate immunity againstAbbreviations: TAK1, transforming growth factor-b-activated kinase
1; TAB1, TAK1-binding protein 1; IL-2, interleukin-2; TCR, T cell
receptor; MAPK, mitogen-activated protein kinase; JNK, c-Jun NH2-
terminal kinase; ERK, extracellular signal-related kinase; MAP3K,
MAPK kinase kinase; AP-1, activator protein-1; NF-jB, nuclear fac-
tor-jB; IKK, IjB kinase; RE/AP, CD28-response element/AP-1-bin-
ding site; TPA, 12-O-tetradecanoylphorbol-13-acetate
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doi:10.1016/j.febslet.2005.10.059gram-negative bacteria is dependent on the TAK1-induced
NF-jB activation in Drosophila [9,10]. Collectively, these ﬁnd-
ings suggest critical roles for TAK1 in inﬂammatory and
immunological responses.
The antigen-induced signaling pathways for T cell activation
through the T cell receptor (TCR) and co-stimulatory molecule
CD28 have been extensively characterized. The binding of
antigen peptide on MHC induces the clustering of a receptor
complex that includes several tyrosine phosphorylated pro-
teins, which recruits downstream signaling molecules including
PKCh, CARMA1, Bcl10, and MALT1 to stimulate the activa-
tion of IKK [11–15]. In addition, the clustering of TCR results
in the activation of all of the three MAPK pathways (ERK,
JNK, p38) leading to AP-1, which have been identiﬁed as crit-
ical pathways regulating IL-2 production [16–21]. The IKK/
NF-jB and MAPKs/AP-1 pathways together target the critical
promoter component consisting of the CD28-responsive ele-
ment and AP-1-binding site (RE/AP) [22–25].
Recently, Sun et al. [11] reported that ubiquitin ligase activ-
ity of TRAF6, an adaptor protein of the IL-1/TLR (TIR) fam-
ily of receptors, and TAK1 are involved in the BCL10- and
MALT1-induced IKK activation in T cells. Although they
showed that RNA interference of TAK1 inhibited partially
TCR-mediated IKK activation and IL-2 production, the pre-
cise role of TAK1 in T cell activation remains largely un-
known. In this study, we have focused on the activation of
endogenous TAK1 and its role in the transcriptional activation
of the RE/AP element in the IL-2 promoter upon T cell activa-
tion. We demonstrated a rapid activation of TAK1, which fol-
lowed activation of the critical IL-2 promoter via the IKK,
JNK and p38 signaling pathways.2. Materials and methods
2.1. Reagents
Anti-phospho-TAK1 (Thr-187) antibody was described previously
[26]. Other phospho-speciﬁc antibodies were obtained form Cell signal-
ing Inc. Antibodies against TAK1, TAK1-binding protein 1 (TAB1),
p38, extracellular signal-related kinase (ERK), and JNK were pur-
chased from Santa Cruz Biotechnologies. 5Z-7-Oxozeanol, a speciﬁc
inhibitor of TAK1, was kindly provided by Dr. Koichiro Ono (Chugai
Pharmacutical Co. Ltd.). Other materials including SP600125, SC-514,
SB203580 (Calbiochem), 12-O-tetradecanoylphorbol-13-acetate (TPA;
Sigma), A23187 (BioVision,Inc), anti-CD3 antibody (eBioscience),
anti-CD28 antibody (BD PharMingen), and protein-A (ICN Biomed-
icals) were obtained commercially.blished by Elsevier B.V. All rights reserved.
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Jurkat cells were maintained in RPMI 1640 medium supplemented
with 10% fetal calf serum, L-glutamine, 100 units/ml penicillin and
100 lg/ml streptomycin at 37 C in 5% CO2. Cells were stimulated with
TPA (100 ng/ml) + A23187 (0.5 lM) or a complex with anti-CD3 anti-
body (3 lg/ml), anti-CD28 antibody (3 lg/ml) and protein A (1 lg/ml).
Jurkat cells were transfected with expression plasmids using Nucle-
ofector (Amaxa) according to the manufacturers instruction. Expres-
sion vectors for TAK1, TAB1, IKKa and IKKb were kindly
provided by Dr. Takahisa Sugita (Tanabe Seiyaku Co. Ltd.) [26].
The reporter plasmids containing four copies of the RE/AP element
were kindly provided by Dr. Arthur Weiss [25].
2.3. Immunoprecipitation and Immunoblotting
Whole cell lysates prepared from Jurkat cells were immunoprecipi-
tated or immunoblotted as described previously [26]. JNK activity
was determined using an in vitro immunocomplex kinase assay [26].
2.4. Electrophoresis mobility shift assay
Electrophoresis mobility shift assay (EMSA) was carried out as
described previously [27]. Nuclear extracts were probed with 32P-
labeled RE/AP and its mutant probes. The sequences is as follows:
RE/AP, 5 0-TTTAAAGAAATTCCAAAGAGTCATCA-3 0; REm/AP,
5 0-TTTAAAGAccTcgaAAAGAGTCATCA-3 0; RE/APm, 5 0-TTTA-
AAGAAATTCCAAAGcaaCATCA-3 0; REm/APm, 5 0-TTTAAA-
GAccTcgaAAAGcaaCATCA.
2.5. Luciferase assay
Cells were cotransfected with reporter plasmids, including the RE/
AP-driven ﬁreﬂy luciferase reporter plasmid and pRL-EF1a luciferase
plasmid (a gift from Dr. Masaaki Tsuda). The luciferase activity was
measured by using the Dual-Luciferase reporter assay kit (Promega).
The RE/AP activity was normalized on the basis of Renilla luciferase
activity.
2.6. ELISA for IL-2
Jurkat cells were transfected with expression vectors or stimulated
with TPA + A23187. After 24 h of incubation, the secretion of IL-2
into the culture supernatants was measured with an ELISA kit (BD
Pharmingen).Fig. 1. Activation of endogenous TAK1 in Jurkat cells. (A) Jurkat
cells were stimulated with 100 ng/ml TPA and 0.5 lM A23187 for the
indicated periods. Immunoprecipitates obtained with anti-TAK1
antibody were immunoblotted with anti-phospho-TAK1, anti-TAK1
and anti-TAB1 antibodies. (B) Jurkat cells were pre-treated with or
without 100 nM 5Z-7-oxozeanol, a speciﬁc inhibitor of TAK1, for
30 min and then stimulated with TPA and A23187 for 5 min.
Immunoblotting was carried out as described in (A).3. Results
3.1. Activation of endogenous TAK1 in T cells
We have identiﬁed Thr-187 as an auto-phosphorylation site
triggering the activation of TAK1 in TNF-a-treated HeLa cells
[26]. No paper has yet reported the activation of TAK1 during
T cell activation. We therefore tried to detect phosphorylated
TAK1 following stimulation with phorbol ester TPA and cal-
cium ionophore A23187 in the Jurkat T cell line (Fig. 1A).
Immunoblotting with an anti-phospho-TAK1 antibody dem-
onstrated a rapid and transient phosphorylation at Thr-187Fig. 2. Involvement of TAK1 in IL-2 production. (A,B) Jurkat cells
were pre-treated with 5Z-7-oxozeanol at the indicated concentration
(nM) for 30 min and then stimulated with TPA + A23187 (A) or anti-
CD3+anti-CD28 antibodies (B). After 24 h of stimulation, the
concentration of IL-2 in the supernatant was measured by ELISA.
The value represents the means ± S.D. for triplicate determinations.
(C) Cells (5 · 105 cells/well in a 48-well plate) were transfected with
expression vectors for wild-type (WT) or kinase-negative (K63W)
TAK1 together with TAB1. After 24 h of transfection, the IL-2
concentration in the supernatant was measured as described in (A).
n.d. means not detected.
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and disappeared at 7.5 min. The onset of phosphorylation of
TAB1 as a shift in mobility on SDS–PAGE correlated with
that of phosphorylation of TAK1; however, it sustained at
least for 20 min. 5Z-7-Oxozeanol, a speciﬁc inhibitor of
TAK1, inhibited partially the phosphorylation of TAK1 and
TAB1 (Fig. 1B). These results suggested a role for the
TAK1-TAB1 complex in T cell activation.
3.2. TAK1-mediated production of IL-2
IL-2 production was measured to evaluate the role of TAK1
in T cell activation. TPA + A23187-induced IL-2 production
was suppressed by a TAK1 inhibitor in a concentration-depen-
dent manner (Fig. 2A). Similarly, the inhibitor blocked IL-2
production via the clustering of a TCR receptor complex with
anti-CD3 and anti-CD28 antibodies (Fig. 2B). To investigateFig. 3. Activation of the RE/AP element within the IL-2 promoter by TAK
Where indicated, cells were pre-treated with 5Z-7-oxozeanol (30 or 100 nM) f
32P-labeled oligonucleotide probes containing wild-type RE/AP (w/w) and it
complexes. (C,D) Jurkat cells were transfected with 4xRE/AP luciferase rep
incubation, cells were pre-treated with 5Z-7-oxozeanol (30 or 100 nM), an
antibodies (D) for 6 h. Luciferase activity was determined by Dual-Luciferase
\, P < 0.01. (E) Jurkat cells were transfected with the wild-type or kinase-nega
AP Luc and pRL-EF1a. Twenty-four hours after transfection, luciferase
determinations.the potential role of TAK1 in IL-2 production, wild-type or ki-
nase-inactive TAK1 was overexpressed with TAB1 in Jurkat
cells. Fig. 2C shows that activation of TAK1 leads to IL-2 pro-
duction, indicating that activation of TAK1 is minimally suﬃ-
cient to induce IL-2 expression. These observations support
the recent ﬁnding that small interfering RNA against TAK1
inhibited partially IL-2 production [11]. Collectively, these
results suggest that TAK1 is functionally involved in IL-2
production.
3.3. Activation of RE/AP element within the IL-2 promoter by
TAK1
Previous studies have reported that a composite element
containing CD28RE and the NF-IL-2B AP-1-binding site
(RE/AP) plays an essential role in the transcriptional regula-
tion of the IL-2 promoter [25]. We tried to investigate the eﬀect1. (A,B) Jurkat cells were stimulated with TPA and A23187 for 4 h.
or 30 min. An electrophoretic mobility shift assay was carried out with
s mutants (m/w, w/m, and m/m). I and II show speciﬁc protein–DNA
orter plasmid and pRL-EF1a Renilla luciferase plasmid. After 24 h of
d then stimulated with TPA + A23187 (C) or anti-CD3+anti-CD28
reporter assay. Data are the means ± S.D. of triplicate determinations.
tive form of TAK1 and TAB1 together with wild-type or mutant 4xRE/
activity was determined. Data are the means ± S.D. of triplicate
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assays with wild-type or mutant DNA probes demonstrated
that two independent DNA-binding activities at CD28RE
and the AP-1-binding site were induced by TPA + A23187
(Fig. 3A). This result is correlated with the observation that
stimulation with anti-TCR antibody, TPA, and anti-CD28
antibody induces two DNA-binding activities on CD28RE
and AP-1-binding site [25]. However, previous reports demon-
strated that both the elements were essential for RE/AP-driven
luciferase gene expression [25]. A TAK1 inhibitor blocked
TPA + A23187-induced RE/AP activity, including the DNA-
binding activities (Fig. 3B) and the reporter gene expression
(Fig. 3C). The RE/AP transcriptional activity by ligation of
TCR with anti-CD3 and anti-CD28 antibodies was also inhib-
ited by the inhibitor (Fig. 3D). In addition, overexpression of
TAK1 with TAB1 potentially induced RE/AP-mediated tran-
scription in a kinase activity-dependent manner (Fig. 3E).
The TAK1-mediated RE/AP activity was dependent on both
CD28RE and the AP-1-binding site because mutation of either
element abolished the luciferase expression (Fig. 3E). These re-
sults demonstrated the functional importance of TAK1 in the
transcriptional regulation of the IL-2 promoter.Fig. 4. TAK1-mediated activation of JNK and p38 is required for IL-23.4. TAK1-mediated activation of the RE/AP element requires
JNK, p38 and IKK
Co-stimulation of Jurkat cells with TPA + A23187-induced
activation of p38 and ERK although their onsets were slightly
diﬀerent (Fig. 4A). The phosphorylations were sustained over
the time period tested and the kinetics of activation of these ki-
nases resembled those of TAB1 as shown in Fig. 1A. Activa-
tion of JNK delayed and was still increasing between 10 and
20 min. TAK1 has been shown to regulate MAPK signaling
pathways; therefore, we examined the eﬀect of a TAK1 inhib-
itor on TPA + A23187-induced MAPK activation. The inhib-
itor suppressed the activation of JNK and p38, whereas the
activation of ERK was only marginally inhibited (Fig. 4B).
TAK1-mediated RE/AP promoter activity was inhibited by
SP600125 and SB203580, inhibitors of JNK and p38, respec-
tively (Fig. 4C). These results indicate that the IL-2 promoter
activity was controlled by TAK1-mediated JNK and p38 sig-
naling pathways.
Activation of CD28RE has been proposed to be regulated
by an IKK-NF-jB pathway. In fact, we conﬁrmed that SC-
514, an IKKb-speciﬁc inhibitor, blocked TPA + A23187-in-
duced IL-2 production (Fig. 5A) and the RE/AP promoter
activity (Fig. 5B). Dominant negative mutants of TAK1 and
IKKb inhibited the RE/AP activity after the stimulation
(Fig. 5C). In addition, TAK1-induced promoter activity was
inhibited by dominant negative mutants of IKKa and IKKb
(Fig. 4D). These results indicate that TAK1-mediated activa-
tion of RE/AP is mediated through the IKK pathway.
promoter activity. (A) Jurkat cells were stimulated with TPA and
A23187 for the indicated periods. Whole cell lysates were immuno-
blotted with anti-phospho-p38, anti-phospho-ERK, anti-p38, anti-
JNK and anti-ERK antibodies. JNK activity was determined by
immunocomplex kinase assay using GST-c-Jun as a substrate. (B)
Jurkat cells were pre-treated with 5Z-7-oxozeanol (100 nM), and then
stimulated with TPA and A23187 for 5 min (p38 and ERK) or 10 min
(JNK). (C) Jurkat cells were transfected with TAK1 and TAB1
together with 4xRE/AP Luc reporter plasmid. Ten minute after
seeding, cells were treated with SB203580 (20 lM) and SP600125
(20 lM) for 24 h. Luciferase activity was determined by Dual-
Luciferase reporter assay. Data are the means ± S.D. of triplicate
determinations.4. Discussion
Several MAP3Ks have been identiﬁed that activate JNK and
p38 MAPK pathways leading to the activation of AP-1. Some
of the stress response MAP3Ks also regulate the NF-jB path-
way by controlling the IKK complex [5–8]. The transcriptional
activity of the RE/AP element within the IL-2 promoter is reg-
ulated coordinately by the JNK, p38 and IKK pathways in Tcells. It has been proposed that some MAP3Ks including Cot/
Tpl2 MEKK1, MEKK2 and MLK3 are involved in this regu-
lation [18,19,21]. However, the precise function of MAP3Ks in
TCR signaling is still controversial.
It has been widely accepted that TAK1 plays a key role in the
activation of JNK, p38 and IKK in response to pro-inﬂamma-
tory factors including TNF-a, IL-1 and ligands for TLR, in
which TAK1 associates with the adaptor protein TRAF2 or
Fig. 5. TAK1-mediated activation of IKK is required for IL-2 promoter activity. (A) Jurkat cells were pre-treated with 30 or 100 lM SC-514, and
then stimulated with TPA and A23187. After 24 h of stimulation, the IL-2 concentration was measured by ELISA. The value represents the
means ± S.D. of triplicate determinations. (B) Cells transfected with 4xRE/AP reporter plasmid were pre-treated with SC-514 (100 lM) or 5Z-7-
oxozeanol (100 nM) and then stimulated with TPA and A23187 for 6 h. Data are the means ± S.D. of triplicate determinations. (C) Cells were
transfected with dominant negative mutants of TAK1 and IKKb together with 4xRE/AP Luc. Twenty-four hours after transfection, cells were
stimulated with TPA and A23187 for 6 h. (D) Cells were transfected with expression vectors for TAK1, TAB1 and dominant negative mutants of
IKKa and IKKb together with reporter plasmids. Twenty-four hours after transfection, luciferase activity was determined.
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TAK1-IKK axis provides for the possible participation of
TAK1 in TCR signaling [11]. We have recently demonstrated
the regulatory mechanism activating the phosphorylation of
TAK1 at Thr-187 in TNF-a-treated HeLa cells [5,26]. In the
present study, immunoblotting with an anti-phospho-TAK1
antibody showed that the phosphorylation of TAK1 at Thr-
187 was also induced in T cells. This is the ﬁrst report showing
the activation of endogenous TAK1 in T cells and suggests that
the phosphorylation at Thr-187 is a common event for activa-
tion of TAK1 by several extracellular stimuli. The transcrip-
tional activation of the IL-2 promoter, shown in this study,
further supports the signiﬁcance of TAK1 in T cell activation.
It is suggested that TAB2 is associated with TCR-mediated
IKK activation in the TRAF6-TAK1-IKK axis in T cells [11].
However, it is unclear whether TAB1 is involved in this process.
Here we demonstrated that phosphorylation of TAK1 is corre-
lated with the phosphorylation of co-immunoprecipitated
TAB1 in Jurkat T cells (Fig. 1A), suggesting that the T cell acti-
vating signal is dependent on the TAK1 and TAB1 complex.
The main regulatory elements in the IL-2 promoter included
not only the compositeRE/APbut also the binding site of nuclear
factor of activated T cells (NFAT). It was recently suggested that
NFATs are functional targets of stress-signaling pathways such
as p38 [29]. Although we demonstrated that TAK1 plays an
important role in T cell activation by controlling the RE/AP ele-
ment, it is necessary to further investigate the role of TAK1 inTCR-mediatedNFATactivation.Thiefes et al. [30] recently iden-
tiﬁed genes whose expression was up/downregulated by infection
with retroviruses encoding an inactivemutantofTAK1 inmurine
ﬁbroblast. Several chemokines aswell asNFATc3were downreg-
ulated, raising a possibility that the expression and activity of the
NFAT proteins are regulated by TAK1 in T cells. Identiﬁcation
of TAK1 target genes in T cells will provide information on the
role of TAK1 in T cell activation.
In summary, TAK1 has been characterized as a kinase reg-
ulating pro-inﬂammatory reactions. In fact, 5Z-7-oxozeanol, a
speciﬁc inhibitor of TAK1, was able to inhibit picryl chloride-
induced ear swelling in vivo [31]. We found that the inhibitor
also suppressed IL-2 secretion in T cells, suggesting that selec-
tive intervention of the activation of TAK1 is likely to have
immunosuppressive potential in the treatment of immunologi-
cal disorders.
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